middle.news
Independent review gives Paradigm’s iPPS program a possible second chance
8:40am on Thursday 19th of November, 2026 AEDT
•
Biotechnology
Read Story
Independent review gives Paradigm’s iPPS program a possible second chance
8:40am on Thursday 19th of November, 2026 AEDT
Key Points
Independent analysis confirms significant ROW benefits for pain, physical function and patient-reported improvement
Overall PARA_OA_012 futility result remains unchanged, with no clear advantage in the full population or US cohort
Paradigm plans to assess a new ROW trial as the near-term development priority
US development remains possible after further data review and FDA consultation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Paradigm Biopharmaceuticals (ASX:PAR)
OPEN ARTICLE